Curaleaf Holdings, Inc. (OTC:CURLF) announced its proposal to acquire Aurora Cannabis Inc. (NASDAQ:ACB) for total implied consideration of $4 per share in cash and stock.
The company went public with its intention following unreturned outreach efforts to Aurora leadership to discuss a potential combination.
No formal takeover bid has been officially launched yet.
• Curaleaf Holdings stock is holding steady today. What should traders watch with CURLF?
Premium Valuation and Deal Terms
The proposed transaction offers Aurora shareholders 0.3463 Curaleaf subordinate voting shares alongside 75 cents in cash for each share.
Based on Aurora’s 30-day volume-weighted average price of $2.75, the proposal reflects a 45% premium, rising to 110% when excluding cash on Aurora’s balance sheet.
The proposal incorporates a maximum consideration cap of $5 per share if Curaleaf stock prices increase significantly before completion.
Curaleaf Chairman and CEO Boris Jordan originally reached out to Aurora Chairman and CEO Miguel Martin on June 23, 2026, followed by a July 7 inquiry, but Aurora declined good faith discussions.
Strategic Global Benefits and Synergies
If finalized, the merged entity would operate across 17 countries with a pro forma market capitalization approaching $3 billion.
The combined enterprise expects to generate over $1.5 billion in the past 12 months revenue and nearly $350 million in the past 12 months’ Adjusted EBITDA.
Curaleaf estimates achieving at least $40 million in annual cost savings through operational efficiencies and supply chain optimization. The deal provides Curaleaf access to Aurora’s annual cultivation capacity exceeding 50 tons, including Safari Flower Company.
Furthermore, the transaction offers Aurora shareholders immediate access to the $32 billion U.S. legal cannabis market alongside Curaleaf’s distribution footprint in key European markets such as Germany, the U.K., and Poland.
Quarterly Earnings
Aurora Cannabis reported a first-quarter 2027 loss of five cents, beating the consensus loss of 13 cents.
Sales $48.798 million, below the consensus of $50.51 million.
The 9% decrease in sales was mainly due to lower quarterly net revenue in Canadian medical cannabis and the wind down in consumer cannabis, offset by higher net revenue in international medical cannabis and wholesale bulk cannabis.
Consolidated adjusted gross margin was 58%.
In April, Aurora closed the acquisition of Safari Flower Company.
Curaleaf reported second quarter earnings of five cents, beating the consensus loss of 17 cents.
Sales jumped 10% year over year to $340.099 million, beating the consensus of $332.284 million.
ACB Stock Price Activity: Aurora Cannabis shares were up 20.07% at $3.47 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Shutterstock
